Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 1, 2025
Data Byte
EMA’s CHMP reaffirms its decision to back Leqembi for Alzheimer’s
Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting
BioCentury | Feb 7, 2025
Finance
Strong demand for Sionna latest good sign for IPOs: Public Equity Report
Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic
BioCentury | Jan 10, 2025
Data Byte
FDA’s new and supplemental approvals in December
Agency approves at least nine new therapies; adds new indications or patient populations to a dozen marketed drugs
BioCentury | Jun 13, 2024
Discovery & Translation
Science Spotlight: Lyell’s scaffold for reenergizing CAR T cells; plus Cirrus, Denali and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 12, 2024
Deals
In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions
Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product
BioCentury | Mar 8, 2024
Finance
Trio of large, crossover-backed rounds lead week’s deals
Alumis raises $259M, Sionna $182M to pursue big opportunities in immunology, cystic fibrosis. Mammen’s FogPharma raises $145M
BioCentury | Feb 6, 2024
Product Development
Clinical roundup: Data for Lilly’s tirzepatide, GSK’s Blenrep, 4D, Vertex and more
Lilly’s dual GLP-1R/GIP agonist shows early efficacy in MASH; Blenrep combo beats Darzalex combo in MM
BioCentury | Nov 16, 2023
Regulation
Scientific achievement, access questions define the world’s first gene editing approval
Casgevy from Vertex and CRISPR gains the first gene editing approval, via U.K. decision
BioCentury | Sep 1, 2023
Finance
The Cystic Fibrosis Powerhouse: Vertex
Back to School 2023 case study: How Vertex kept raising the bar to dominate a therapeutic space
BioCentury | Apr 27, 2023
Product Development
April 27 Quick Takes: AbbVie exits CF based on triplet’s readout
Plus: AZ cuts late-stage GLP-1, Wilson’s disease programs and updates from Sanofi, 4D Molecular, Generate
Items per page:
1 - 10 of 132